Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines in adults.^[8][6] It is given by injection under the skin.^[8][6]

The most common side effect is pain and redness at the site of injection.^[8] Other side effects include allergic reactions.^[8] It is in the calcitonin gene-related peptide antagonist class of medications.^[8]

It was approved for medical use in the United States in 2018,^[8] the European Union in 2019,^[7] the UK in 2020^[4] and Argentina by September 2021.^[9]

Fremanezumab was shown to be effective in adults with four or more attacks per month.^[10]

The most common adverse effects are reactions at the injection site, which occurred in 43 to 45% of people in studies (as compared to 38% under placebo). Hypersensitivity reactions occurred in fewer than 1% of patients.^[6][11]

Fremanezumab does not interact with other antimigraine drugs such as triptans, ergot alkaloids and analgesics. It is expected to generally have a low potential for interactions because it is not metabolized by cytochrome P450 enzymes.^[6]

Fremanezumab was discovered and developed by Rinat Neuroscience, was acquired by Pfizer in 2006, and was then licensed to Teva.^[13] It was approved by the US Food and Drug Administration in September 2018.^[14] In March 2019, fremanezumab was approved for marketing and use in the European Union.^[7][15]

The drug has been and is still^[when?] being evaluated for diseases other than migraine, where the endogenous substance CGRP has been implicated in the pathology.^{[citation needed]} Teva is still^[when?] developing it for episodic cluster headache but stopped development of fremanezumab for the treatment of chronic cluster headache in 2018 after the primary endpoint of a Phase III trial was not met.^{[16][needs update]}

Fremanezumab is a humanized monoclonal antibody.^[17] It is produced using recombinant DNA in Chinese hamster ovary cells.^[18]